-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on RAPT Therapeutics, Lowers Price Target to $1

Benzinga·05/22/2025 12:55:18
Listen to the news
UBS analyst Eliana Merle maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $2 to $1.